PPCB Company Profile and Key Details

PPCB has shown weak momentum, losing -34.05% over the past week and -81.09% over the past quarter, though year-to-date performance is down -44.32%. Short-term trend indicators are bullishly aligned (SMA20 -36.38%, SMA50 -63.98%, SMA200 -93.07%). The stock’s 14-day RSI is 27.18 (weak momentum), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.16% below its high and over 11.36% above its low. Average 10-day trading volume of 5.82 million shares is significantly above the 3-month average of 2.09 million, indicating heightened recent market interest.

Propanc Biopharma, Inc. generated EPS of -$46.23 over the past year. Five-year average earnings growth is 98.33%.

Propanc Biopharma, Inc. (NASDAQ:PPCB) closed at $0.20 USD, gaining $0.01 (5.71%) from the previous close of $0.19. The stock is currently mid-range between its 52-week high and low $0.16 and $11.00. With a market capitalization of about $2.59 million, Propanc Biopharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.50). Key stats such as the average daily volume over the past year has been around 387.81 thousand shares, trading with heavier-than-usual volume. Headquartered in Camberwell, VIC, Propanc Biopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James Nathanielsz, the company employs approximately 1 people and listed since November 12, 2012. Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia.

Propanc Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.43. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Propanc Biopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -70.28%, with price expected at $0.06 by February 18, 2026, within a range of $0.00 to $0.11 3-Month Outlook: Projected fall of -10.85%, reaching $0.18 by May 05, 2026, with a range of $0.17 to $0.18. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by February 04, 2027, within a range of $0.00 to $0.01.

Propanc Biopharma, Inc. (NASDAQ:PPCB) shares are down -44.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Propanc Biopharma, Inc. trading at a premium to the broader market with a P/E of -0.04. Our AI forecast model points to short-term weakness (-70.28% over two weeks), a medium-term fall (-10.85% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Propanc Biopharma, Inc. trades at a P/E ratio of -0.04, slightly below the S&P 500 average, with a price-to-sales ratio of 89.72 and a price-to-book ratio of 0.18 suggesting the stock is closer to book value. The P/FCF stands at -1.27, also above market averages.